Evidence map›Paper›PMID 28526920›Full record

Trial reportDiabetologia2017

Effects of semaglutide on beta cell function and glycaemic control in participants with type 2 diabetes: a randomised, double-blind, placebo-controlled trial.

Christoph Kapitza, Kirsten Dahl, Jacob B Jacobsen, Mads B Axelsen, Anne Flint

2 registry-linked trialsOpen access · hybridFull text readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02128932. Cited by 53 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed, 4 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02128932 phase3completed

Efficacy and Safety of Semaglutide Once Weekly Versus Insulin Glargine Once Daily as Add on to Metformin With or Without Sulphonylurea in Insulin-naïve Subjects With Type 2 Diabetes

Ran2014Enrolled1,089Registered outcomes8Posted comparisons2ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsInsulin glargine, semaglutide
PMID 29862621PMID 30615985PMID 28344112PMID 30865526PMID 29687620PMID 29766634other papers from this trial
Open the trial in the graph
NCT02212067 phase1completed

A Single-centre, Randomised, Double-blind, Multiple-dose, Placebo-controlled, Parallel-group Trial Investigating the Effects of Semaglutide on ß-cell Function in Subjects With Type 2 Diabetes

Ran2014Enrolled87Registered outcomes8Posted comparisons0ConditionsDiabetes, Diabetes Mellitus, Type 2ArmsPlacebo, semaglutide
Open the trial in the graph
3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 4 syntheses or guidelines pooled it, 106 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Review
  18. [Semaglutide-induced acute-on-chronic liver failure: A case report and literature review].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Christoph KapitzaProfil Institut für Stoffwechselforschung GmbH, Hellersbergstrasse 9, 41460, Neuss, Germany. christoph.kapitza@profil.com.
Kirsten DahlNovo Nordisk A/S, Søborg, Denmark.
Jacob B JacobsenNovo Nordisk A/S, Søborg, Denmark.
Mads B AxelsenNovo Nordisk A/S, Søborg, Denmark.
Anne FlintNovo Nordisk A/S, Søborg, Denmark.
Novo Nordisk (Denmark) · DKProfil Institute for Metabolic Research · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisSemaglutide is a glucagon-like peptide-1 analogue in development for the treatment of type 2 diabetes. Its effects on first- and second-phase insulin secretion and other measures of beta cell function and glycaemic control were assessed.

methodsIn this single-centre, double-blind, placebo-controlled, parallel-group trial, conducted at the Profil Institut für Stoffwechselforschung, Germany, 75 adult (aged 18-64 years) participants with type 2 diabetes (eligibility: HbA

resultsIn total, 37 participants received semaglutide and 38 received placebo. Following IVGTT, for insulin, both AUC CONCLUSIONS/

interpretationTwelve weeks of once-weekly treatment with semaglutide significantly improved beta cell function and glycaemic control in participants with type 2 diabetes.

trial registrationClinicalTrials.gov NCT02212067

fundingThe study was funded by Novo Nordisk A/S.

Indexed as

AdolescentAdultBlood GlucoseDiabetes Mellitus, Type 2Double-Blind MethodFemaleGlucagon-Like PeptidesGlycated HemoglobinHumansHypoglycemic AgentsInsulin-Secreting CellsMetforminMiddle AgedPregnancySemaglutideYoung AdultBlood GlucoseGlucagon-Like PeptidesGlycated HemoglobinHypoglycemic AgentsMetforminSemaglutideBeta cell functionGlycaemic controlPlacebo-controlled trialSemaglutideType 2 diabetes

Identifiers

PMID28526920
PMCPMC5491562
OpenAlexW2614548128

What Socratic holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.